Switching from Reservoir to Matrix Systems for the Transdermal Delivery of Fentanyl: A Prospective, Multicenter Pilot Study in Outpatients with Chronic Pain Rainer Freynhagen, MD, Hans Jürgen von Giesen, MD, PhD, Peter Busche, MD, Rainer Sabatowski, MD, PhD, Christhoph Konrad, MD, PhD, Stefan Grond, MD Journal of Pain and Symptom Management Volume 30, Issue 3, Pages 289-297 (September 2005) DOI: 10.1016/j.jpainsymman.2005.03.015 Copyright © 2005 U.S. Cancer Pain Relief Committee Terms and Conditions
Fig. 1 The average, minimum, and maximum pain intensity in all patients over the entire study period measured using an 11-point numeric rating scale (NRS) (0 = no pain, 10 = worst possible pain) and the average sleep interference used to assess how pain interfered with sleep during the preceding 24 hours (0 = pain does not interfere with sleep to 10 = pain completely interferes with sleep). Journal of Pain and Symptom Management 2005 30, 289-297DOI: (10.1016/j.jpainsymman.2005.03.015) Copyright © 2005 U.S. Cancer Pain Relief Committee Terms and Conditions
Fig. 2 Patients' self-assessment at the removal of each patch (n = 46). Patients were asked to describe the condition of the skin under the removed patch as being normal, slightly or badly reddened, weeping, or blistered. The skin at the application sites was more frequently badly reddened, weeping, or blistered after removal of the reservoir system (33%) than after removal of the first matrix system (6%, P < 0.05) and the second matrix system (2%, P < 0.05). Journal of Pain and Symptom Management 2005 30, 289-297DOI: (10.1016/j.jpainsymman.2005.03.015) Copyright © 2005 U.S. Cancer Pain Relief Committee Terms and Conditions